| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Istituto di Clinica delle Malattie del Sistema Nervoso, Facoltá di Medicina e Chirurgia, Universitá di Torino, Italy.
We conducted a double-blind trial of high-dose parenteral 6-methylprednisolone (MP) and placebo on 23 patients with acute MS. After the double-blind trial, the patients were given corticosteroids in gradually decreasing doses. The frequency of improvement was significantly higher and the bout duration significantly lower in the MP group than in the placebo group. The first signs of improvement (3 to 6 days after starting MP) were associated with a marked decrease in the rate of CNS IgG synthesis, but IgG CSF oligoclonal bands did not change. CNS IgG production slowly returned toward baseline despite progressive clinical improvement.
Address correspondence and reprint requests to Dr. Durelli, Clinica Neurologica, Universitá di Torino, Via Cherasco, 15, 1–10126 Torino, Italy.
Accepted for publication June 14, 1985.
This article has been cited by other articles:
|
|
 |
|
  W. H. Stuart and P. Vermersch Concomitant therapy for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S28 - S34. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Nos, J. Sastre-Garriga, C. Borrlas, J. Rio, M. Tintore, and X. Montalban Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis Multiple Sclerosis, August 1, 2004; 10(4): 413 - 416. [Abstract] [PDF]
|
|
|
|
|
|
F Sellebjerg, C V Jensen, H B. Larsson, and J L Frederiksen Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis Multiple Sclerosis, February 1, 2003; 9(1): 102 - 107. [Abstract] [PDF]
|
|
|
|
|
|
R. Zivadinov, R. A. Rudick, R. De Masi, D. Nasuelli, M. Ukmar, R. S. Pozzi-Mucelli, A. Grop, G. Cazzato, and M. Zorzon Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS Neurology, October 9, 2001; 57(7): 1239 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M Miller, B. Weinstock-Guttman, F. Bethoux, J.-C. Lee, G. Beck, V. Block, L. Durelli, L. LaMantia, D. Barnes, F. Sellebjerg, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Multiple Sclerosis, August 1, 2000; 6(4): 267 - 273. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Schmidt, R. Gold, L. Schonrock, U. K. Zettl, H.-P. Hartung, and K. V. Toyka T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy Brain, July 1, 2000; 123(7): 1431 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sellebjerg, H. S. Nielsen, J. L. Frederiksen, and J. Olesen A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis Neurology, April 1, 1999; 52(7): 1479 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H L Tremlett, D K Luscombe, and C M Wiles Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom J. Neurol. Neurosurg. Psychiatry, September 1, 1998; 65(3): 362 - 365. [Abstract] [Full Text]
|
|
|
|
|
|
H. S Panitch Investigational drug therapies for treatment of multiple sclerosis Multiple Sclerosis, September 1, 1996; 2(2): 66 - 77. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Miller, D. Bourdette, P. Ritvo, W. Stuart, and T. Vollmer The Neurologist's Perspective: What Do We Know and Where Do We Go? Neurorehabil Neural Repair, January 1, 1994; 8(3): 105 - 111. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Compston Methylprednisolone and Multiple Sclerosis Arch Neurol, June 1, 1988; 45(6): 669 - 670. [Abstract] [PDF]
|
|
|
|
|
|
R. Troiano, S. D. Cook, and P. C. Dowling Steroid Therapy in Multiple Sclerosis: Point of View Arch Neurol, August 1, 1987; 44(8): 803 - 807. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
